Arg-Gly-Glu-Ser TFA

Name: Arg-Gly-Glu-Ser TFA
Brand: MedChemExpress
SKU: HY-P0309A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P0309A Purity: 99.39%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Arg-Gly-Glu-Ser TFA is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Arg-Gly-Glu-Ser TFA Chemical Structure

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	USD 136	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	USD 136	In-stock	Estimated Time of Arrival: December 31
Solid
2 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 190	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 390	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 690	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Arg-Gly-Glu-Ser TFA:

Arg-Gly-Glu-Ser Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Arg-Gly-Glu-Ser TFA is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.

In Vivo

Arg-Gly-Glu-Ser (5 mg/kg) in combination with LPS or saline + RGDS does not affect neutrophil and macrophage cell numbers and has no effect on protein accumulation compared with LPS- or saline-treated mice, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

561.47

Formula

C₁₈H₃₀F₃N₇O₁₀

Appearance

Solid

Color

White to off-white

Sequence

Arg-Gly-Glu-Ser

Sequence Shortening

RGES

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 20 mg/mL (35.62 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7810 mL	8.9052 mL	17.8104 mL
5 mM	0.3562 mL	1.7810 mL	3.5621 mL
10 mM	0.1781 mL	0.8905 mL	1.7810 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (178.10 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.39%

Select Batch:

Data Sheet (272 KB) SDS (252 KB)

COA (248 KB) LCMS (105 KB)

Handling Instructions (2659 KB)

References

[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18. [Content Brief]

Animal Administration
^[1]

Mice^[1]
Mouse pharyngeal aspiration is performed in the assay. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with RGDS or Arg-Gly-Glu-Ser peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered RGDS or Arg-Gly-Glu-Ser peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	1.7810 mL	8.9052 mL	17.8104 mL	44.5260 mL
	5 mM	0.3562 mL	1.7810 mL	3.5621 mL	8.9052 mL
	10 mM	0.1781 mL	0.8905 mL	1.7810 mL	4.4526 mL
	15 mM	0.1187 mL	0.5937 mL	1.1874 mL	2.9684 mL
	20 mM	0.0891 mL	0.4453 mL	0.8905 mL	2.2263 mL
	25 mM	0.0712 mL	0.3562 mL	0.7124 mL	1.7810 mL
	30 mM	0.0594 mL	0.2968 mL	0.5937 mL	1.4842 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.